# Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

> **NCT00963495** · PHASE1 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 11 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Myelodysplasia
- Lymphoma, Non-Hodgkin
- Hodgkin's Lymphoma
- Multiple Myeloma

## Interventions

- **DRUG:** Clioquinol

## Key facts

- **NCT ID:** NCT00963495
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2015-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00963495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00963495, "Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00963495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*